EUVIMEDEUVIMED entdecken
Open Access

Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics

J Hunter Fly, Jeremy S Stultz, Lea S Eiland

The Journal of Pediatric Pharmacology and Therapeutics · 2026-06 · 31 (3) · 322-338

DOI: 10.5863/jppt-25-00075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-06. Verfasst von J Hunter Fly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Translational Science (JHF), The University of Tennessee Health Science Center College of Pharmacy, Memphis, TN. Die Arbeit nennt 198 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a major contributor to global morbidity and mortality, disproportionately affecting young children and infants. Annual worldwide estimates suggest more than 30 million cases of lower respiratory infection and 100,000 deaths are attributed to RSV in children younger than 5 years of age, making RSV prevention and treatment a global priority. Recently approved monoclonal antibodies and vaccines for the prevention of RSV in infants and children have the potential to significantly alter disease burden. Disease prevention is paramount as treatments with rigorously proven clinical efficacy are limited, and supportive care remains the primary management strategy for the majority of patients who contract RSV. However, new entities continue to be evaluated for the treatment of RSV in the pediatric population. This review aimed to synthesize and evaluate existing data on the approved RSV preventative therapies nirsevimab, RSVpreF, clesrovimab, and palivizumab. RSV disease, including its spread, virology, diagnosis, clinical presentation, and treatment, is also discussed.

Schlagwörter

Stichwörter der Autor:innen

infantmonoclonal antibodiesneonatepediatricsrespiratory syncytial virus infectionsrespiratory syncytial virus vaccine

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Translational Science (JHF), The University of Tennessee Health Science Center College of Pharmacy, Memphis, TN.
  • Department of Clinical Pharmacy and Translational Science (JSS), The University of Tennessee Health Science Center College of Pharmacy, Nashville, TN.
  • Department of Pharmacy Practice (LSE), Auburn University Harrison College of Pharmacy, Auburn, AL.

Zitieren

APA

Fly, J. H., Stultz, J. S., & Eiland, L. S. (2026). Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics. The Journal of Pediatric Pharmacology and Therapeutics, 31(3), 322-338. https://doi.org/10.5863/jppt-25-00075

Vancouver

Fly JH, Stultz JS, Eiland LS. Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(3):322-338. doi:10.5863/jppt-25-00075

BibTeX
@article{Fly2026,
  author = {Fly, J Hunter and Stultz, Jeremy S and Eiland, Lea S},
  title = {Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics},
  journal = {The Journal of Pediatric Pharmacology and Therapeutics},
  year = {2026},
  volume = {31},
  number = {3},
  pages = {322--338},
  doi = {10.5863/jppt-25-00075}
}
Kostenlos starten →